SCHEMBL3397222

SCHEMBL3397222

OC(Nc1cnc(Br)cn1)c1c(-c2ccc(F)cc2)nc2cnc(Br)cn12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.34
TUBB4A P04350 2/20 0.31
TUBB P07437 2/20 0.31
TUBA3C P0DPH7 2/20 0.31
TUBA1B P68363 2/20 0.31
TUBA4A P68366 2/20 0.31
TUBB4B P68371 2/20 0.31
TUBB3 Q13509 2/20 0.31
TUBB2A Q13885 2/20 0.31
TUBB8 Q3ZCM7 2/20 0.31
TUBA3E Q6PEY2 2/20 0.31
TUBA1A Q71U36 2/20 0.31
TUBA1C Q9BQE3 2/20 0.31
TUBB6 Q9BUF5 2/20 0.31
TUBB2B Q9BVA1 2/20 0.31
TUBB1 Q9H4B7 2/20 0.31
TGFBR1 P36897 3/20 0.31
TP53 P04637 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3392032 0.89 MAPT (0.35) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3395134 0.86 MAPK14 (0.35) MAPK14TGFBR1CSNK1D
SCHEMBL3395127 0.79 AHR (0.37) MAPK14TGFBR1TP53POLBMAPT
SCHEMBL3395285 0.78 CRHR1 (0.38) MAPK14
SCHEMBL14632158 0.77 GAA (0.30) MAPK14
SCHEMBL3393708 0.75 ALDH1A1 (0.31) TGFBR1MAPTALDH1A1
SCHEMBL3393907 0.74 TP53 (0.45) TGFBR1TP53POLBMAPTKDM4E
SCHEMBL14632083 0.72 GABRD (0.38) TP53MAPTALDH1A1CSNK1D
SCHEMBL1691297 0.71 GABRA1 (0.44) TGFBR1TP53POLBMAPTCSNK1D
SCHEMBL12781602 0.68 MAPT (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS BIOVITRUM AB (PUBL) (SE) 2015-08-27 US disclosed
US-20140206662-A1 Imidazopyridine Compounds PROXIMAGEN LTD. (GB) 2014-07-24 US disclosed
EP-2376490-B1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD (GB) 2013-01-23 EP disclosed
WO-2010064020-A1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD. (GB) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS SSB, MIF, IDO1 MAPK14 3550/4885TUBB4A 4036/4885TUBB 3984/4885
US-20140206662-A1 Imidazopyridine Compounds SSB, NFKBIA, TPMT MAPK14 2099/4885TUBB4A 3567/4885TUBB 3680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.